Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

被引：39

作者：

Janjigian, Y. Y. ^{[1
]}

Al-Batran, S-E. ^{[2
]}

Wainberg, Z. A. ^{[3
]}

Van Cutsem, E. ^{[4
,5
]}

Molena, D. ^{[6
]}

Muro, K. ^{[7
]}

Hyung, W. J. ^{[8
]}

Wyrwicz, L. S. ^{[9
]}

Oh, D. Y. ^{[10
,11
]}

Omori, T. ^{[12
]}

Moehler, M. ^{[13
]}

Garrido, M. ^{[14
,15
]}

Oliveira, S. Cunha Sousa ^{[16
]}

Liberman, M. ^{[17
]}

Oliden, V. Castro ^{[18
]}

Bilici, M. ^{[19
]}

Kurland, J. F. ^{[20
]}

Xynos, I. ^{[21
]}

Mann, H. ^{[21
]}

Tabernero, J. ^{[22
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, New York, NY USA

[2] Univ Canc Ctr, Inst Clin Canc Res, Krankenhaus Nordwest, Frankfurt, Germany

[3] UCLA, David Geffen Sch Med, Dept Gastrointestinal Med Oncol, Los Angeles, CA USA

[4] Univ Hosp Leuven, Dept Gastroenterol Digest Oncol, Leuven, Belgium

[5] Katholieke Univ Leuven, Leuven, Belgium

[6] Mem Sloan Kettering Canc Ctr, Div Thorac Surg, New York, NY USA

[7] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[8] Yonsei Univ, Dept Surg, Coll Med, Seoul, South Korea

[9] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Radiotherapy & Oncol, Warsaw, Poland

[10] Seoul Natl Univ Hosp, Div Med Oncol, Dept Internal Med, Seoul, South Korea

[11] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea

[12] Osaka Int Canc Inst, Dept Gastroenterol Surg, Osaka, Japan

[13] Johannes Gutenberg Univ Clin, Res Ctr Immunotherapy FZI, Mainz, Germany

[14] SAGA Clin Trial Ctr, Hemato Oncol Dept, Santiago, Chile

[15] Univ Mayor, Santiago, Chile

[16] Clin Res Ctr, Northern Riograndense League Canc, Clin Oncol, Natal, RN, Brazil

[17] Ctr Hosp Univ Montreal Ctr Rech CHUM, Dept Surg, Div Thorac Surg, Montreal, PQ, Canada

[18] Natl Inst Neoplast Dis INEN, Med Oncol Dept, Lima, Peru

[19] Ataturk Univ, Dept Med Oncol, Fac Med, Erzurum, Turkiye

[20] AstraZeneca, Oncol R&D, Late Stage Dev, Gaithersburg, MD USA

[21] AstraZeneca, Oncol R&D, Late Stage Dev, Cambridge, England

[22] UVic UCC, Vall Hebron Hosp Campus & Inst Oncol VHIO, Dept Med Oncol, IOB Quiron, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.074

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA73

引用

页码：S1315 / S1316

页数：2

共 50 条

[21] MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - a randomized, double-blind, placebo-controlled, phase 3 study
Janjigian, Yelena
Van Cutsem, Eric
Muro, Kei
Wainberg, Zev
Al-Batran, Salah-Eddin
Hyung, Woo Jin
Molena, Daniela
Evans, Brent
Ruscica, Dario
Robbins, Scott H.
Negro, Alejandra
Tabernero, Josep
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 94 - 94
[22] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Al-Batran, Salah-Eddin
Homann, Nils
Pauligk, Claudia
Goetze, Thorsten O.
Meiler, Johannes
Kasper, Stefan
Kopp, Hans-Georg
Mayer, Frank
Haag, Georg Martin
Luley, Kim
Lindig, Udo
Schmiegel, Wolff
Pohl, Michael
Stoehlmacher, Jan
Folprecht, Gunnar
Probst, Stephan
Prasnikar, Nicole
Fischbach, Wolfgang
Mahlberg, Rolf
Trojan, Joerg
Koenigsmann, Michael
Martens, Uwe M.
Thuss-Patience, Peter
Egger, Matthias
Block, Andreas
Heinemann, Volker
Illerhaus, Gerald
Moehler, Markus
Schenk, Michael
Kullmann, Frank
Behringer, Dirk M.
Heike, Michael
Pink, Daniel
Teschendorf, Christian
Loehr, Carmen
Bernhard, Helga
Schuch, Gunter
Rethwisch, Volker
von Weikersthal, Ludwig Fischer
Hartmann, Joerg T.
Kneba, Michael
Daum, Severin
Schulmann, Karsten
Weniger, Joerg
Belle, Sebastian
Gaiser, Timo
Oduncu, Fuat S.
Guentner, Martina
Hozaeel, Wael
Reichart, Alexander
LANCET, 2019, 393 (10184): : 1948 - 1957
[23] MONEO: Phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC)
Alsina, M.
Ponz-Sarvise, M.
Garcia, D. Lopez
Villacampa, G.
De Andrea, C.
Ochoa, C.
Lopez-Janeiro, A.
Jimenez-Fonseca, P.
Arrazubi, V.
Garcia, M. Diez
Sanz-Garcia, E.
de Castro, E. Martinez
Sanchez, R. Guardeno
Campos, M. Calvo
Sanchez, C. Buges
Longo, F.
Navarro, V.
Gros, A.
Vivancos, A.
Tabernero, J.
Munoz, S.
Melero, I.
ANNALS OF ONCOLOGY, 2023, 34 : S2 - S3
[24] MONEO: A phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC).
Alsina, Maria
Ponz-Sarvise, Mariano
Garcia, Dario Lopez
Gonzalez, Marta
De Andrea, Carlos E.
Gros, Alena
Vivancos, Ana
Jimenez-Fonseca, Paula
Garcia, Marc Diez
Arrazubi, Virginia
Sanz-Garcia, Enrique
de Castro, Eva Martinez
Guardeno, Raquel
Calvo, Mariona
Buges, Cristina
Longo, Federico
Tabernero, Josep
Villacampa, Guillermo
Munoz, Susana
Melero, Ignacio
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[25] Randomized, phase II study comparing cisplatin and high-dose 5-fluorouracil/leucovorin with paclitaxel and high-dose 5-fluorouracil/leucovorin in patients with advanced gastric cancer and adenocarcinomas of the gastroesophageal junction
Tesselaar, M. E.
Luelmo, S.
Polee, M.
van Bochove, A.
Ouwerkerk, J.
Pruijt, H.
Sleeboom, H.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[26] Pathological response to neoadjuvant 5-FU, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO
Pauligk, C.
Tannapfel, A.
Meiler, J.
Luley, K. B.
Kopp, H. G.
Homann, N.
Hofheinz, R. D.
Schmalenberg, H.
Probst, S.
Haag, G. M.
Egger, M.
Behringer, D. M.
Stoehlmacher, J.
Prasnikar, N.
Block, A.
Trojan, J.
Folprecht, G.
Pohl, M.
Schirmacher, P.
Al-Batran, S. E.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S728 - S728
[27] Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO
Pauligk, Claudia
Tannapfel, Andrea
Meiler, Johannes
Luley, Kim Barbara
Kopp, Hans-Georg
Homann, Nils
Hofheinz, Ralf Dieter
Schmalenberg, Harald
Probst, Stephan
Haag, Georg Martin
Egger, Matthias
Behringer, Dirk M.
Stoehlmacher, Jan
Prasnikar, Nicole
Block, Andreas
Trojan, Jorg
Koenigsmann, Michael
Schmiegel, Wolff
Jaeger, Elke
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[28] MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer-A randomized, double-blind, placebo-controlled, phase 3 study.
Janjigian, Yelena Y.
Van Cutsem, Eric
Muro, Kei
Wainberg, Zev A.
Al-Batran, Salah-Eddin
Hyung, Woo Jin
Molena, Daniela
Evans, Brent
Ruscica, Dario
Robbins, Scott H.
Negro, Alejandra
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[29] Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up
Rosenberg, Ari Joseph
Rademaker, Alfred
Hochster, Howard S.
Ryan, Theresa
Hensing, Thomas
Shankaran, Veena
Baddi, Lisa
Mahalingam, Devalingam
Mulcahy, Mary F.
Benson, Al B., III
ONCOLOGIST, 2019, 24 (08): : 1039 - +
[30] Interim safety results from a phase II/III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: A study of the AIO.
Koock, Ulrike
Pauligk, Claudia
Luley, Kim Barbara
Mayer, Frank
Schulmann, Karsten
Homann, Nils
Schmalenberg, Harald
Hozaeel, Wael
Hofheinz, Ralf
Probst, Stephan
Mahlberg, Rolf
Koenigsmann, Michael
Haag, Georg Martin
Meiler, Johannes
Prasnikar, Nicole
Behringer, Dirk M.
Trojan, Jorg
Egger, Matthias
Jaeger, Elke
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →